QLS5133 / Qilu Pharma - LARVOL DELTA

QLS5133-a novel CDH6-targeting antibody-drug-conjugate for solid tumors (AACR 2025) - "Additionally, QLS5133 was able to achieve a durable response even after resistance to Mirvetuximab soravtansine (FRα ADC/ImmunoGen) in preclinical models. The promising efficacy, superior tolerability, and favorable PK profile support the potential of QLS5133 as a novel therapeutic agent to address the high unmet needs in patients with variable CDH6-expressing cancers. QLS5133 will enter clinical trials."

ADC • Endocrine Cancer • Genito-urinary Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Thyroid Gland Carcinoma • CDH6 • FOLR1

A Study of QLS5133 Monotherapy in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=212 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.

Monotherapy • New P1/2 trial • Solid Tumor